Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea : Episode 4

Inside MAJIC-PV: A Closer Look at the Patient Population

May 8, 2024

By Gabriela Hobbs, MD
Timothy Mok, PharmD, BCPS, BCOP

Opinion

Video

Gabriela Hobbs, MD, describes characteristics of the patient population included in the MAJIC-PV study, and analyzes best available therapies received in the comparator arm.

EP: 1.Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera

EP: 2.The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance

EP: 3.Objectives and Study Design of MAJIC-PV

Now Viewing

EP: 4.Inside MAJIC-PV: A Closer Look at the Patient Population

EP: 5.Key Findings from MAJIC-PV

EP: 6.Safety Analysis and Interpreting Results from MAJIC-PV

EP: 7.Key Takeaways Following MAJIC-PV

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!